The DOI matches its Crossref record; 234 of the 236 references it cites were found in a registry or an index.
p21 in cancer: intricate networks and multiple activities
Open accessAbstract
One of the main engines that drives cellular transformation is the loss of proper control of the mammalian cell cycle. The cyclin-dependent kinase inhibitor p21 (also known as p21WAF1/Cip1) promotes cell cycle arrest in response to many stimuli. It is well positioned to function as both a sensor and an effector of multiple anti-proliferative signals. This Review focuses on recent advances in our understanding of the regulation of p21 and its biological functions with emphasis on its p53-independent tumour suppressor activities and paradoxical tumour-promoting activities, and their implications in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“p21 is a potent cell-cycle inhibitor (39)”
From Txnip Enhances Fitness of Dnmt3a -Mutant Hematopoietic Stem Cells via p21 (2022) · cites this paper as [39]
In the citing paper
“CDKN1A (p21, WAF1, CIP1) was among the first p53 target genes11, 12 to be identified and is now recognized as an encoder for a major cell cycle checkpoint control protein.145”
From Census and evaluation of p53 target genes (2017) · cites this paper as [145]
In the citing paper
“As p21 is rarely genetically affected in cancers [1,124]”
From CDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication (2020) · cites this paper as [1]
In the citing paper
“Members of the Krüppel-like factor (KLF) transcription factor (TF) family can activate the CDKN1A gene by cooperating with p300-CREBBP (Aliouat-Denis et al., 2005; Abbas and Dutta, 2009).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Abbas and Dutta, 2009
In the citing paper
“p21WAF1/CIP1 can also be activated by p53 independent mechanisms by other stimulators such as nuclear receptors including androgen, vitamin D and retinoid receptors.”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Abbas and Dutta, 2009
In the citing paper
“Although this is the first detectable event, it is more likely that main role of p21 lies in its capacity to trigger pRb-mediated repression of cell cycle regulators (Fig. 2, for more information on p21 functions (see ref. 98 ).”
From Senescence from G2 arrest, revisited (2015) · cites this paper as [98]
In the citing paper
“For example, cyclin-dependent kinase inhibitor 1A (CDKN1A), a tumor suppressor that is downregulated in multiple cancers (106), is targeted by at least 28 miRNAs and many of which are upregulated together in cancers where CDKN1A has been implicated (107).”
From Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation (2018) · cites this paper as [106]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“CDK1, at least in some tissues, may be the crucial target of p21 in tumorigenesi”
BackgroundRequirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Xu, X., Yuan, G., Li, Q., Shan, S.-L., & Jiang, S. (2012) · Hepatogastroenterology · doi:10.5754/hge12404 · Cited by 1,825
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“Recent work suggests that tumour regression can be achieved through the reactivation of senescence, for example by restoring p53 functio”
BackgroundPCNA, the Maestro of the Replication Fork
Moldovan, G.-L., Pfander, B., & Jentsch, S. (2007) · Cell · doi:10.1016/j.cell.2007.05.003 · Cited by 1,796
Cellular senescence in cancer and aging.
Collado, M., Blasco, M. A., & Serrano, M. (2007) · Cell · doi:10.1016/j.cell.2007.07.003 · Cited by 1,708
Flagged first, then by citations
2 of the 236 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Martin-Caballero, J., Flores, J. M., Garcia-Palencia, P. & Serrano, M. Tumor susceptibility of p21Waf1/Cip1-deficient mice. Cancer Res. 61, 6234–6238 (2001). This study demonstrates that deletion of Cdkn1a in mice results in spontaneous tumours but with late onset.
Cited by
Sorted by citations
Items 301–400 of 1,005
Tsitsipatis, D., Grammatikakis, I., Driscoll, R. K., Yang, X., Abdelmohsen, K., Harris, S. C., Yang, J., Herman, A. B., Chang, M., Munk, R. B., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1246 · Cited by 79
Liu, B., Peng, Z., Zhang, H., Zhang, N., Liu, Z., Xia, Z., Huang, S., Luo, P., & Cheng, Q. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02284-z · Cited by 86
Lansu, K., & Gentile, S. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.174 · Cited by 80
Cryptotanshinone, a Stat3 inhibitor, suppresses colorectal cancer proliferation and growth in vitro
Li, W., Saud, S. M., Young, M. R., Colburn, N. H., & Hua, B. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2424-0 · Cited by 80
Stein, J., Majores, M., Rohde, M., Lim, S., Schneider, S., Krappe, E., Ellinger, J., Dietel, M., Stephan, C., Jung, K., et al. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.05.022 · Cited by 80
Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation
Fiorentino, F. P., Tokgün, P. E., Solé‐Sánchez, S., Giampaolo, S., Tokgün, O., Jauset, T., Kohno, T., Perucho, M., Soucek, L., & Yokota, J. (2016) · Oncotarget · doi:10.18632/oncotarget.8826 · Cited by 80
Comparative Study of the Mode of Action of Clinically Approved Platinum-Based Chemotherapeutics
Schoch, S., Gajewski, S., Rothfuß, J., Hartwig, A., & Köberle, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186928 · Cited by 76
CITED2 functions as a molecular switch of cytokine-induced proliferation and quiescence
Chou, Y.-T., Hsieh, C.-H., Chiou, S.-H., Hsu, C.-F., Kao, Y.-R., Lee, C.-C., CHUNG, C. ‐., Wang, Y.-H., Hsu, H.-S., Pang, S.-T., et al. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.91 · Cited by 77
Wong, P., Miranda, F., Chan, K. V., Berlato, C., Hurst, H. C., & Scibetta, A. G. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06373-11 · Cited by 79
Ryl, T., Kuchen, E. E., Bell, E., Shao, C., Flórez, A. F., Mönke, G., Gogolin, S., Friedrich, M., Lamprecht, F., Westermann, F., et al. (2017) · Cell Systems · doi:10.1016/j.cels.2017.07.005 · Cited by 79
Small-Molecule Inhibitors of the p53-MDM2 Interaction
Vu, B. T., & Vassilev, L. T. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_110 · Cited by 82
Zhao, X., Zhou, L., Li, X., Ni, J., Chen, P., Ma, R., Wu, J., & Feng, J. (2018) · Cancer Medicine · doi:10.1002/cam4.1710 · Cited by 78
Molecular mechanisms of the action of Arctigenin in cancer
He, Y., Fan, Q., Cai, T., Huang, W., Xie, X., Wen, Y., & Shi, Z. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.158 · Cited by 78
The NUCKS1-SKP2-p21/p27 axis controls S phase entry
Hume, S., Grou, C. P. O., Lascaux, P., D’Angiolella, V., Legrand, A. J., Ramadan, K., & Dianov, G. L. (2021) · Nature Communications · doi:10.1038/s41467-021-27124-8 · Cited by 81
Chen, A., Huang, X., Zhenan, X., Cao, D., Huang, K., Chen, J., Pan, Y., & Gao, Y. (2015) · Medical science monitor basic research/Medical science monitor. Basic research · doi:10.12659/msmbr.893608 · Cited by 79
Pellecchia, A., Pescucci, C., Lorenzo, E. D., Luceri, C., Passaro, N., Sica, M., Notaro, R., & Angioletti, M. D. (2012) · Oncogenesis · doi:10.1038/oncsis.2012.20 · Cited by 77
Wang, S., Tie, J., Wang, R. Y., Hu, F., Gao, L., Wang, W., Wang, L., Li, Z., Hu, S., Tang, S., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.12.045 · Cited by 78
Anantharaju, P. G., Reddy, D. B., Mahesh, P. A., Chitturi, C. M. K., Vimalambike, M. G., & Madhunapantula, S. V. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186208 · Cited by 80
Heldt, F. S., Barr, A. R., Cooper, S., Bakal, C., & Novák, B. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1715345115 · Cited by 81
Andreani, A., Granaiola, M., Locatelli, A., Morigi, R., Rambaldi, M., Varoli, L., Calonghi, N., Cappadone, C., Farruggia, G., Stefanelli, C., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2012694 · Cited by 76
5-Ene-4-thiazolidinones induce apoptosis in mammalian leukemia cells
Senkiv, J., Finiuk, N. S., Kaminskyy, D. V., Havrylyuk, D., Wojtyra, M., Kril, I., Gzella, A. K., Stoika, R. S., & Lesyk, R. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.089 · Cited by 76
Mirza‐Aghazadeh‐Attari, M., Darband, S. G., Kaviani, M., Mihanfar, A., Aghazadeh-Attari, J., Yousefi, B., & Majidinia, M. (2018) · DNA repair · doi:10.1016/j.dnarep.2018.07.005 · Cited by 79
Regulation of cell cycle drivers by Cullin-RING ubiquitin ligases
Jang, S., Redon, C. E., Thakur, B. L., Bahta, M., & Aladjem, M. I. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00508-4 · Cited by 76
Genome homeostasis defects drive enlarged cells into senescence
Manohar, S., Estrada, M. E., Uliana, F., Vuina, K., Alvarez, P. M., de Bruin, R. A. M., & Neurohr, G. E. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.10.018 · Cited by 85
Sham, C. L., To, K. F., Chan, P. K. S., Lee, D. L. Y., Tong, M. C. F., & van Hasselt, C. A. (2011) · Head & Neck · doi:10.1002/hed.21772 · Cited by 76
BRD4 regulates cellular senescence in gastric cancer cells via E2F/miR-106b/p21 axis
Dong, X., Hu, X., Chen, J., Hu, D., & Chen, L.-F. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0181-6 · Cited by 75
Kang, D. Y., Sp, N., Lee, J., & Jang, K. (2021) · Biomedicines · doi:10.3390/biomedicines9030297 · Cited by 75
Molecular mechanisms of melatonin’s inhibitory actions on breast cancers
Proietti, S., Cucina, A., Reiter, R. J., & Bizzarri, M. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1161-8 · Cited by 75
CDK/CCN and CDKI Alterations for Cancer Prognosis and Therapeutic Predictivity
Bonelli, P., Tuccillo, F. M., Borrelli, A., Schiattarella, A., & Buonaguro, F. M. (2014) · BioMed Research International · doi:10.1155/2014/361020 · Cited by 75
Braun, F., Bertin-Ciftci, J., Gallouët, A.-S., Millour, J., & Juin, P. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023577 · Cited by 75
Shirakami, Y., Gottesman, M. E., & Blaner, W. S. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr275 · Cited by 75
Origanti, S., Cai, S.-R., Munir, A. Z., White, L. S., & Piwnica-Worms, H. (2013) · Oncogene · doi:10.1038/onc.2012.84 · Cited by 74
Darżynkiewicz, Z., Zhao, H., Zhang, S., Lee, M., Lee, E. Y. C., & Zhang, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.4149 · Cited by 74
Huang, Y., Tong, S., Tai, A. W., Hussain, M., & Lok, A. S.-F. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.048 · Cited by 74
Sirtuins in Cancer: a Balancing Act between Genome Stability and Metabolism
Jeong, S. M., & Haigis, M. C. (2015) · Molecules and Cells · doi:10.14348/molcells.2015.0167 · Cited by 74
XAF1 directs apoptotic switch of p53 signaling through activation of HIPK2 and ZNF313
Lee, M. G., Han, J., Jeong, S.-I., Her, N.-G., Lee, J., Ha, T.-K., Kang, M. J., Ryu, B., & Chi, S.-G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411746111 · Cited by 73
Cheng, F., Liu, C., Lin, C.-C., Zhao, J., Jia, P., Li, W., & Zhao, Z. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004497 · Cited by 73
Shi, T., Mazumdar, T., DeVecchio, J., Duan, Z.-H., Agyeman, A., Aziz, M. A., & Houghton, J. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013054 · Cited by 75
Han, J., Yl, K., Lee, K.-W., Her, N.-G., Ha, T.-K., Yoon, S., Jeong, S.-I., Lee, J.-H., Kang, M. J., Lee, M.-G., et al. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.33 · Cited by 72
SOCS1 in cancer: An oncogene and a tumor suppressor
Beaurivage, C., Champagne, A., Tobelaim, W. S., Pomerleau, V., Menéndez, A., & Saucier, C. (2016) · Cytokine · doi:10.1016/j.cyto.2016.01.005 · Cited by 73
Ashrafian, H., O′Flaherty, L., Adam, J., Steeples, V., Chung, Y., East, P., Vanharanta, S., Lehtonen, H. J., Nye, E. L., Hatipoglu, E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1949 · Cited by 72
Wu, B., Jiang, Y., Zhu, F., Sun, D., & He, X. (2017) · Technology in Cancer Research & Treatment · doi:10.1177/1533034617700559 · Cited by 72
Charoensinphon, N., Qiu, P., Dong, P., Zheng, J., Ngauv, P., Cao, Y., Li, S., Ho, C., & Xiao, H. (2013) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201300136 · Cited by 72
Potapova, T., Seidel, C. W., Box, A., Rancati, G. I., & Li, R. (2016) · Molecular Biology of the Cell · doi:10.1091/mbc.e16-05-0268 · Cited by 68
Hussain, T., Saha, D., Purohit, G., Kar, A., Mukherjee, A. K., Sharma, S., Sengupta, S., Dhapola, P., Maji, B., Sreekanth, V., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11177-1 · Cited by 70
ATM: Functions of ATM Kinase and Its Relevance to Hereditary Tumors
Ueno, S., Sudo, T., & Hirasawa, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010523 · Cited by 75
Wadhwa, S., & Mumper, R. J. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.05.027 · Cited by 72
Wu, P., Hong, S., Veeranki, S., Karkhanis, M. S., Starenki, D., Plaza, J. A., & Park, J. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00021-13 · Cited by 71
The potential role of miRNAs and exosomes in chemotherapy in ovarian cancer
Alharbi, M. G., Zuñiga, F. A., Elfeky, O. W. M., Guanzon, D., Lai, A., Rice, G. E., Perrin, L. C., Hooper, J. D., & Salomón, C. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0019 · Cited by 73
Kong, Y., Zhang, L., Huang, Y., He, T., Zhang, L., Zhao, X., Zhou, X., Zhou, D., Yan, Y., Zhou, J., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.07.031 · Cited by 70
SKA3 Promotes tumor growth by regulating CDK2/P53 phosphorylation in hepatocellular carcinoma
Hou, Y., Wang, Z., Huang, S., Sun, C., Zhao, J., Shi, J., Li, Z., Wang, Z., He, X., Tam, N. L., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2163-3 · Cited by 70
p53: A double-edged sword in tumor ferroptosis
Ji, H., Wang, W., Li, X., Han, X., Zhang, X., Wang, J., Liu, C., Huang, L., & Gao, W. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106013 · Cited by 71
Ticli, G., Cazzalini, O., Stivala, L. A., & Prosperi, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137058 · Cited by 72
Bi, H.-L., Li, S., Qu, X., Wang, M., Bai, X., Xu, Z., Ao, X., Jia, Z., Jiang, X., Yang, Y., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.247 · Cited by 71
Smet, F. D., Rubio, M. S., Hompes, D., Naus, E., Baets, G. D., Langenberg, T., Hipp, M. S., Houben, B., Claes, F., Charbonneau, S. K., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4872 · Cited by 75
Na, K., Li, K., Sang, T., Wu, K., Wang, Y., & Wang, X. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3939 · Cited by 70
Cooperative p16 and p21 action protects female astrocytes from transformation
Kfoury, N., Sun, T., Yu, K., Rockwell, N., Tinkum, K. L., Qi, Z., Warrington, N. M., McDonald, P. R., Roy, A., Weir, S. J., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0513-5 · Cited by 70
Yuan, S., Han, Y., Ma, M., Rao, K., Wang, Z., Yang, R., Liu, Y., & Zhou, X. (2019) · Environmental Pollution · doi:10.1016/j.envpol.2019.03.109 · Cited by 69
SKIP counteracts p53-mediated apoptosis via selective regulation of p21Cip1 mRNA splicingPreprint
Chen, Y., Zhang, L., & Jones, K. A. (2011) · Genes & Development · doi:10.1101/gad.2002611 · Cited by 72
Cisplatin-induced senescence in ovarian cancer cells is mediated by GRP78
Li, W., Wang, W., Dong, H., Li, Y., Li, L., Han, L., Han, Z., Wang, S., Ma, D., & Wang, H. (2014) · Oncology Reports · doi:10.3892/or.2014.3147 · Cited by 69
EZH2 promotes gastric cancer cells proliferation by repressing p21 expression
Xu, J., Wang, Z., Lu, W., Jiang, H., Lu, J., Qiu, J. G., & Ye, G. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.03.003 · Cited by 69
Zhou, L., Yu, Y., Sun, S., Zhang, T., & Wang, M. (2018) · Journal of Cancer · doi:10.7150/jca.25213 · Cited by 68
Li, M., Li, Z., Sun, X., Yang, L., Fang, P., Liu, Y., Li, W. X., Xu, J., Lu, J., Xie, M., et al. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07581.x · Cited by 68
Frión-Herrera, Y., Díaz-García, A., Ruiz-Fuentes, J. L., Rodríguez-Sánchez, H., & Sforcin, J. M. (2015) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12449 · Cited by 67
Lee, Y.-S., Choi, K.-M., Kim, W., Jeon, Y.-S., Lee, Y., Hong, J. T., Yun, Y., & Yoo, H. (2013) · Journal of Natural Products · doi:10.1021/np4005135 · Cited by 71
Inactivation of TGF-β signaling and loss of PTEN cooperate to induce colon cancer in vivo
Yu, M., Trobridge, P. A., Wang, Y., Kanngurn, S., Morris, S. M., Knoblaugh, S. E., & Grady, W. M. (2013) · Oncogene · doi:10.1038/onc.2013.102 · Cited by 71
Chen, R.-J., Tsai, S.-J., Ho, C., Pan, M., Ho, Y., Wu, C., & Wang, Y. (2012) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf302778a · Cited by 68
An Overview of Ultraviolet B Radiation-Induced Skin Cancer Chemoprevention by Silibinin
Kumar, R., Deep, G., & Agarwal, R. (2015) · Current Pharmacology Reports · doi:10.1007/s40495-015-0027-9 · Cited by 71
Hu, J., Chen, Z., Xia, D., Wu, J. P., Xu, H., & Ye, Z. (2012) · Biochemical Journal · doi:10.1042/bj20120256 · Cited by 68
Kleinschmidt, M. A., de Graaf, P., van Teeffelen, H. A. A. M., & Timmers, H. T. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041446 · Cited by 68
Cyclic depsipeptides as potential cancer therapeutics
Kitagaki, J., Shi, G., Miyauchi, S., Murakami, S., & Yang, Y. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000183 · Cited by 70
Zhao, S., Guo, J., Zhao, Y., Fei, C., Zheng, Q., Li, X., & Chang, C. (2016) · Europe PMC (PubMed Central) · Cited by 68
Shikonin Inhibits Cancer Through P21 Upregulation and Apoptosis Induction
Wang, F., Pozo, F. M., Tian, D., Geng, X., Yao, X., Zhang, Y., & Tang, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00861 · Cited by 68
Mutational signatures reveal the role of RAD52 in p53-independent p21-driven genomic instability
Galanos, P., Pappas, G., Polyzos, A., Kotsinas, A., Svolaki, I., Giakoumakis, N. N., Glytsou, C., Pateras, I. S., Swain, U., Souliotis, V. L., et al. (2018) · Genome Biology · doi:10.1186/s13059-018-1401-9 · Cited by 67
Li, Y., Li, D., Zhao, M., Huang, S., Zhang, Q., Lin, H., Wang, W., Li, K., Li, Z., Huang, W., et al. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.07.032 · Cited by 67
Kianamiri, S., Dinari, A., Sadeghizadeh, M., Rezaei, M., Daraei, B., Bahsoun, N. E.-H., & Nomani, A. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00566 · Cited by 68
Li, G., Fang, S., Shao, X., Li, Y., Tong, Q., Kong, B., Chen, L., Wang, Y., Yang, J. J., Yu, H., et al. (2021) · Biomolecules · doi:10.3390/biom11091295 · Cited by 67
Regulation of thymidylate synthase: an approach to overcome 5-FU resistance in colorectal cancer
Kumar, A., Singh, A. K., Singh, H., Thareja, S., & Kumar, P. (2022) · Medical Oncology · doi:10.1007/s12032-022-01864-z · Cited by 74
Bisteau, X., Paternot, S., Bianca, C., Ecker, K., Coulonval, K., Groote, P. D., Declercq, W., Hengst, L., & Roger, P. P. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003546 · Cited by 68
Kai, M., Kanaya, N., Wu, S. V., Mendez‐Dorantes, C., Nguyen, D. M., Luu, T. H., & Chen, S. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3376-5 · Cited by 67
Eitsuka, T., Tatewaki, N., Nishida, H., KURATA, T., Nakagawa, K., & Miyazawa, T. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.09.126 · Cited by 67
Orlando, S., Gallastegui, E., Besson, A., Abril, G., Aligué, R., Pujol, M. J., & Bachs, O. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv593 · Cited by 67
Singer, S., Zhao, R., Barsotti, A. M., Ouwehand, A., Fazollahi, M., Coutavas, E. E., Breuhahn, K., Neumann, O., Longerich, T., Pusterla, T., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.09.020 · Cited by 69
Jeon, J.-S., Kwon, S., Ban, K., Hong, Y. K., Ahn, C., Sung, J., & Choi, I. (2019) · Nutrition and Cancer · doi:10.1080/01635581.2018.1559929 · Cited by 67
Lian, Y., Yang, J., Lian, Y., Xiao, C., Hu, X., & Xu, H. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0333-9 · Cited by 66
Hwang, J. R., Kim, W. Y., Cho, Y., Ryu, J., Choi, J., Jeong, S. Y., Kim, M.-S., Kim, J. H., Paik, E. S., Lee, Y.-Y., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03242-x · Cited by 68
At a Crossroads to Cancer: How p53-Induced Cell Fate Decisions Secure Genome Integrity
Rizzotto, D., Englmaier, L., & Villunger, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910883 · Cited by 69
SIRT1/FOXO Signaling Pathway in Breast Cancer Progression and Metastasis
Dilmaç, S., Kuşçu, N., Caner, A., Yıldırım, S., Yoldaş, B., Farooqı, A. A., & Tanrιöver, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810227 · Cited by 68
PBRM1, SETD2 and BAP1 — the trinity of 3p in clear cell renal cell carcinoma
Walton, J., Lawson, K. A., Prinos, P., Finelli, A., Arrowsmith, C. H., & Ailles, L. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00659-1 · Cited by 74
Kocher, B. A., & Piwnica-Worms, D. R. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0503 · Cited by 67
14-3-3 Proteins Play a Role in the Cell Cycle by Shielding Cdt2 from Ubiquitin-Mediated Degradation
Dar, A., Wu, D., Lee, N. C. J., Shibata, E., & Dutta, A. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00838-14 · Cited by 65
Self-citationA facile in vitro platform to study cancer cell dormancy under hypoxic microenvironments using CoCl2
Lee, H. R., Leslie, F., & Azarin, S. M. (2018) · Journal of Biological Engineering · doi:10.1186/s13036-018-0106-7 · Cited by 67
Construction of a computable cell proliferation network focused on non-diseased lung cells
Westra, J. W., Schlage, W. K., Frushour, B. P., Gebel, S., Catlett, N. L., Han, W., Eddy, S. F., Hengstermann, A., Matthews, A. L., Mathis, C., et al. (2011) · BMC Systems Biology · doi:10.1186/1752-0509-5-105 · Cited by 63
β-Caryophyllene Induces Apoptosis and Inhibits Angiogenesis in Colorectal Cancer Models
Dahham, S. S., Tabana, Y., Asif, M., Ahmed, M., Babu, D., Hassan, L. E. A., Ahamed, M. B. K., Sandai, D. A., Barakat, K., Siraki, A. G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910550 · Cited by 65
Papadimitriou, M., Pazaiti, A., Iliakopoulos, K., Markouli, M., Michalaki, V., & PAPADIMITRIOU, C. A. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119346 · Cited by 68
Zhao, J., Fu, W., Liao, H.-Y., Dai, L., Jiang, Z., Pan, Y., Huang, H., Mo, Y., Li, S., Yang, G., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1713-z · Cited by 65
Sw, W., Wang, S. S. W., Wu, D.-C., Lin, Y.-C., Ku, C., Wu, C., Chai, C.-Y., Lee, J.-N., Tsai, E.-M., Lin, C.-L., et al. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.420 · Cited by 65
Identification of XBP1-u as a novel regulator of the MDM2/p53 axis using an shRNA library
Huang, C., Wu, S., Ji, H., Yan, X., Xie, Y., Murai, S., Zhao, H., Miyagishi, M., & Kasim, V. (2017) · Science Advances · doi:10.1126/sciadv.1701383 · Cited by 67
p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation
Xia, M., Knezevic, D., & Vassilev, L. T. (2011) · Oncogene · doi:10.1038/onc.2010.413 · Cited by 64
Overexpression of PLOD3 promotes tumor progression and poor prognosis in gliomas
Tsai, C., Huang, L., Tsai, W., Huang, S., Lee, J., & Hueng, D. (2018) · Oncotarget · doi:10.18632/oncotarget.24594 · Cited by 63
Metadata
- Authors
- Abbas, T., & Dutta, A.
- Affiliations
- University of Virginia (US)
- Corresponding author
- Abbas, Tarek
- Dutta, Anindya
- Venue
- Nature Reviews Cancer
- Published
- 2009-05-14
- Volume
- 9
- Issue
- 6
- Pages
- 400-414
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC2722839
- OpenAlex
- W2162262059
- Cited by
- 2,712
- References
- 236
- Citations by year
- 2026: 99 · 2025: 156 · 2024: 161 · 2023: 206 · 2022: 182 · 2021: 205 · 2020: 204 · 2019: 180 · 2018: 191 · 2017: 196 · 2016: 148 · 2015: 160 · 2014: 142 · 2013: 151 · 2012: 122
- FWCI
- 9.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R01CA089406, R01 CA 89406, T32CA009109)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p21, cyclin-dependent kinase inhibitors, cell cycle arrest, therapeutic target, cell transformation
- MeSH terms
- Animals, Cell Cycle, Humans, Neoplasms, Tumor Suppressor Protein p53, Cyclin-Dependent Kinase Inhibitor p21
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
